Best Stocks to Buy in July 2026: 10 High-Conviction Picks for the Second Half

As we enter the second half of 2026, the macroeconomic landscape has finally found an equilibrium. The Federal Reserve has successfully anchored the terminal rate near 3.75%, inflation remains structurally contained at 2.2%, and the U.S. economy is enjoying a robust mid-cycle expansion. We are no longer in the speculative frenzy of the early AI boom; instead, we have entered the deployment and monetization phase, where corporate earnings must justify valuations.

For institutional and retail investors alike, the H2 2026 playbook demands a barbell approach: anchoring portfolios with high-quality, cash-generating mega-caps while selectively deploying capital into high-growth mid-caps that are disrupting legacy markets.

Below are our 10 high-conviction stock picks for July 2026, spanning five critical sectors.

Artificial Intelligence & Semiconductors

The semiconductor sector has bifurcated. While legacy chipmakers face cyclical headwinds, companies powering the artificial intelligence infrastructure—and the emerging edge-AI ecosystem—continue to command premium valuations justified by extraordinary earnings growth.

NVIDIA Corporation (NASDAQ: NVDA)

• Current Price: $172.50
• Forward P/E: 31.4x
• Price Target: $210.00
• Why it’s a buy now: The market vastly underestimated the upgrade supercycle driven by Nvidia's Rubin architecture, which began shipping in volume in Q2 2026. Hyperscalers are not pulling back on CapEx; they are doubling down on inference compute. Nvidia’s transition from a pure hardware vendor to a platform-as-a-service provider via its NIM (Nvidia Inference Microservices) software layer is driving a structural expansion in gross margins to 77%.
• Key Risks: The primary risk is a potential pause in data center CapEx if major tech companies fail to demonstrate sufficient ROI from their internal AI tools, leading to temporary order digestions.

ARM Holdings plc (NASDAQ: ARM)

• Current Price: $185.20
• Forward P/E: 68.5x
• Price Target: $230.00
• Why it’s a buy now: As AI processing moves from the cloud to the edge (smartphones, PCs, and IoT devices), ARM is the undisputed gatekeeper. The mass adoption of the ARM v9 architecture, which commands double the royalty rates of its predecessor, is driving unparalleled bottom-line growth. With AI-enabled PCs capturing 40% of new laptop sales this summer, ARM’s compute subsystems are rapidly stealing market share from legacy x86 architectures.
• Key Risks: ARM trades at a premium growth multiple. Any macroeconomic shock that depresses global consumer electronics refresh cycles could trigger a sharp valuation contraction.

Actionable Takeaway for AI/Semiconductors

Do not try to time the top in foundational AI hardware. Maintain overweight exposure to the infrastructure providers, but pivot new capital allocations toward edge-compute architectures that benefit from the ongoing hardware refresh cycle.

Healthcare

Healthcare in 2026 is defined by two megatrends: the normalization of the GLP-1 weight-loss market and a renaissance in targeted biotechnology following a massive wave of M&A activity in 2025.

Eli Lilly and Company (NYSE: LLY)

• Current Price: $1,150.00
• Forward P/E: 42.1x
• Price Target: $1,350.00
• Why it’s a buy now: Supply chain bottlenecks for Zepbound and Mounjaro are fully resolved. More importantly, our channel checks indicate exceptional clinical progress for Orforglipron, Lilly’s once-daily oral GLP-1 pill, which is poised to disrupt the injectable market. Lilly is no longer just a pharma company; it is a consumer health behemoth with deep structural moats and expanding operating leverage.
• Key Risks: Political pricing pressure is escalating ahead of the midterm elections, and aggressive pushback from pharmacy benefit managers (PBMs) could compress net realized prices.

Vertex Pharmaceuticals (NASDAQ: VRTX)

• Current Price: $542.80
• Forward P/E: 26.3x
• Price Target: $620.00
• Why it’s a buy now: Vertex has successfully diversified away from its cystic fibrosis monopoly. The recent commercial launch of Suzetrigine, its non-opioid pain medication, is tracking 40% above consensus estimates as hospital systems mandate non-addictive pain protocols. Furthermore, the Casgevy gene-editing therapy is seeing accelerated patient onboarding globally, solidifying a lucrative new recurring revenue stream.
• Key Risks: Vertex's valuation remains heavily reliant on seamless execution in its pipeline. Any unexpected safety signals in real-world data for its newly commercialized therapies could derail momentum.

Actionable Takeaway for Healthcare

Shift focus from clinical trial speculation to commercial execution. Prioritize companies that have successfully transitioned their pipeline blockbusters into scalable, high-margin commercial products.

Financials

With the yield curve firmly normalized and the Fed funds rate resting at 3.75%, net interest margins for large institutions have stabilized. The current environment favors elite capital allocators and disruptive fintechs capturing underbanked demographics.

JPMorgan Chase & Co. (NYSE: JPM)

• Current Price: $245.30
• Forward P/E: 12.5x
• Price Target: $285.00
• Why it’s a buy now: JPMorgan is the ultimate all-weather compounder. The return of a steepening yield curve is structurally beneficial to JPM’s massive deposit base. Furthermore, global investment banking activity has rebounded sharply in 2026, driven by corporate spin-offs and leveraged buyouts. JPM is capturing a disproportionate share of this fee pool while returning aggressive amounts of capital via its recently authorized $35 billion buyback program.
• Key Risks: A sudden spike in consumer credit defaults, particularly in the subprime auto and credit card segments, could force higher loan loss provisions and compress near-term EPS.

Nu Holdings Ltd. (NYSE: NU)

• Current Price: $19.45
• Forward P/E: 22.8x
• Price Target: $26.00
• Why it’s a buy now: Nubank has conquered Brazil and is now replicating its hyper-growth model in Mexico and Colombia. The thesis is playing out flawlessly: cross-selling high-margin credit and investment products to a captive, digital-first customer base. Cost-to-serve metrics remain a fraction of legacy Latin American banks, and return on equity (ROE) is currently sustaining an incredible 28%.
• Key Risks: Foreign exchange volatility and localized macroeconomic instability in Latin America can create severe, albeit temporary, drawdowns in dollar-denominated earnings.

Actionable Takeaway for Financials

Use the banking sector as the ballast of your portfolio. Pair a fortress-balance-sheet money center bank with a high-growth emerging market fintech to capture both steady dividend yield and aggressive capital appreciation.

Consumer Staples

The 2026 consumer is resilient but highly selective. Inflation has cooled, but cumulative price increases over the last four years have fundamentally altered shopping behaviors, heavily favoring omnichannel retail dominance and premium-yet-accessible lifestyle brands.

Walmart Inc. (NYSE: WMT)

• Current Price: $88.10
• Forward P/E: 25.2x
• Price Target: $102.00
• Why it’s a buy now: Walmart has successfully transformed from a traditional discount retailer into a diversified commerce platform. The high-margin Walmart Connect advertising business is now generating over $5 billion annually, and automated supply chain investments have finally made the company’s e-commerce operations highly accretive to net margins. Walmart is the safest equity to hold if consumer spending decelerates.
• Key Risks: The stock is trading at a premium multiple relative to its historical average. Any margin compression stemming from aggressive price-cutting to fend off international competitors like Shein/Temu could spark a multiple contraction.

Celsius Holdings, Inc. (NASDAQ: CELH)

• Current Price: $82.50
• Forward P/E: 38.6x
• Price Target: $115.00
• Why it’s a buy now: After consolidating in 2024 and 2025, Celsius is breaking out again due to its international expansion. The PepsiCo distribution partnership has fully penetrated the European and UK markets, shifting the revenue mix. Domestically, Celsius continues to capture shelf space from legacy energy drinks by leaning into the "functional wellness" beverage trend, demonstrating immense pricing power.
• Key Risks: The functional beverage space has extremely low barriers to entry. Sustained marketing spend is required to defend market share, which can periodically pressure operating margins.

Actionable Takeaway for Consumer Staples

Do not mistake "staples" for "stagnant." Target staples companies that possess a secondary, high-growth revenue driver—such as an advertising network or rapid international market penetration—to ensure growth outpaces inflation.

Energy

The energy sector in 2026 is defined by strict capital discipline. Massive production surges have been replaced by a laser focus on free cash flow generation, aggressive share repurchases, and base dividend growth.

Exxon Mobil Corporation (NYSE: XOM)

• Current Price: $135.60
• Forward P/E: 13.1x
• Price Target: $155.00
• Why it’s a buy now: The integration of Pioneer Natural Resources is complete, and Exxon is extracting unprecedented efficiencies from its Permian Basin acreage. Exxon’s break-even price has dropped to under $35 per barrel. With Brent crude stabilizing in the $75–$80 range, the company is generating tidal waves of free cash flow, supporting a 4% dividend yield and a relentless buyback cadence.
• Key Risks: A sudden de-escalation of geopolitical tensions combined with a flood of OPEC+ spare capacity hitting the market could suppress global crude prices for a prolonged period.

Diamondback Energy, Inc. (NASDAQ: FANG)

• Current Price: $230.40
• Forward P/E: 11.2x
• Price Target: $275.00
• Why it’s a buy now: Following its successful acquisition of Endeavor Energy, Diamondback is now the premier pure-play operator in the Permian. The company's contiguous acreage allows for massive lateral drilling efficiencies. FANG's variable dividend policy directly rewards shareholders during commodity price spikes, making it an excellent hedge against unforeseen inflationary shocks in late 2026.
• Key Risks: As a pure-play Permian operator, Diamondback lacks the geographic and downstream diversification of the supermajors, leaving it highly sensitive to basin-specific takeaway constraints or localized regulatory shifts.

Actionable Takeaway for Energy

Treat the energy sector as your portfolio's cash flow engine and inflation hedge. Focus exclusively on low-cost operators in tier-one basins who prioritize shareholder return frameworks over production growth at any cost.

Ready to Analyze Your Next Investment?

Get a free AI-powered fair value analysis on any stock. See intrinsic value, margin of safety, and institutional-grade risk metrics in seconds. No credit card required.

Want full access to our institutional research tools? Explore Invest Daily Pro.